Consider Tesla (TSLA) for its cluster of potential near-term catalysts in Q3, including a major Full Self-Driving (FSD) update and a potential sales surge before the US tax credit expires on September 30th. The recent sell-off in Hims & Hers Health (HIMS) is presented as a buying opportunity, as the market is incorrectly valuing it solely as a GLP-1 weight-loss company. HIMS is positioned as a long-term disruptive telehealth platform with major growth catalysts ahead in menopause treatments and international expansion. For a leveraged, long-term play on Bitcoin, look at MicroStrategy (MSTR), the analyst's largest holding. View any price weakness in MSTR as an opportunity to gain exposure to Bitcoin as a hedge against long-term fiat currency debasement.

MicroStrategy (MSTR)

• The speaker identifies MSTR as their largest portfolio position and a long-term hold they plan to own in 2030 and beyond.
• The recent price decline is attributed to negative sentiment and frustration around the company's ATM (At-The-Market) stock offering, not a fundamental problem with the business or Bitcoin.
• The speaker notes that MSTR's stock has fallen more than Bitcoin itself, which they believe is "doing just fine."
• Despite the recent drop, the stock is highlighted as an outstanding performer, delivering a 23x to 28x return over the past five years, depending on the entry point.
• A key part of the discussion is the stock's Price to Net Asset Value (NAV), which is currently around 1.5. This means investors are paying a 50% premium for the Bitcoin held by the company.
• The speaker challenges the standard calculation of NAV, arguing that:
  • Convertible debt should not be treated as traditional debt. Instead, it should be viewed as "future dilution" that will be converted into stock at a higher price, which is ultimately beneficial (accretive) for long-term shareholders.
  • Perpetual preferreds should not be valued at their face value since they will never be paid back, and the fiat-based interest payments will become insignificant over time due to inflation.
• The core investment thesis is that dilution is a feature, not a bug. MSTR issues new shares to raise capital, which it then uses to buy more Bitcoin, driving long-term returns for shareholders.

Takeaways

• MSTR is presented as a long-term, leveraged play on Bitcoin. The speaker is extremely bullish, viewing the company as a vehicle for accumulating Bitcoin and benefiting from the long-term devaluation of fiat currency.
• Investors should understand that the investment case relies on accepting share dilution as the primary mechanism for growth. The company's strategy is to use its stock's premium to NAV to acquire more Bitcoin.
• The current negative sentiment and price drop could be seen as a buying opportunity for those who share the long-term bullish view on Bitcoin and Michael Saylor's strategy.
• The speaker considers this a "pure money debasement play" and a bet that Bitcoin has no top because fiat has no bottom.

Hims & Hers Health (HIMS)

• The speaker is very confident in HIMS, their third-largest position, which they started buying between $6 and $10 per share.
• The recent stock sell-off is attributed to a messy Q2 caused by a supplier issue (Novo Nordisk backing out), not poor execution by HIMS. The speaker expects the company to "pick back up."
• The market is incorrectly viewing HIMS as only a GLP-1 (weight loss drug) company. The weight loss segment is only about 20% of the business.
• HIMS is described as a disruptive, vertically integrated telehealth company with a powerful business model:
  • It takes "cash cow" blockbuster drug categories (ED, hair loss, mental health) and turns them into convenient subscription services.
  • It is vertically integrated, with its own pharmacies, labs, and the ability to manufacture its own peptides (like liraglutide).
  • It uses AI to help its 1,500+ medical professionals prescribe medication more efficiently.
• The speaker compares the potential disruption of HIMS to that of Amazon (AMZN) in its early days.
• Future Growth Catalysts:
  • New treatments for menopause and testosterone (HRT) are planned for 2025.
  • International expansion into Europe (via the Zava acquisition) and Canada.
  • In Canada, they are launching semaglutide after Novo Nordisk lost its patent there.
• The company's weight-loss strategy is robust, offering cheaper alternatives like liraglutide and oral pills that show comparable results for many patients, capitalizing on the societal trend of using prescriptions for weight loss.

Takeaways

• The speaker is very bullish on HIMS, viewing it as a "hyper-growth" company trading at a "very cheap price."
• The investment thesis is that the market misunderstands the company, focusing too much on a single product category (GLP-1s) while ignoring its diversified, vertically integrated business model and multiple future growth drivers.
• Investors should be prepared for high volatility, which the speaker notes is the "price you pay for high returns," similar to what early Amazon investors experienced.
• The key opportunity is the potential for HIMS to disrupt numerous multi-billion dollar "cash cow" segments of the traditional healthcare and pharmacy industry.

Tesla (TSLA)

• The speaker identifies TSLA as their second-largest position and believes it's "about time for prime time" after being "dead money" for the past four years.
• The core, long-term thesis of self-driving technology is described as "finally happening."
• A wave of significant near-term catalysts is expected in Q3:
  • Full Self-Driving (FSD): A major update with "10x parameters" is expected within weeks, which could be an "enormous catalyst."
  • Robotaxi: The service is expanding in Austin and San Francisco, with plans for New York City.
  • Auto Sales Boost: A surge in sales is anticipated before September 30th as US buyers rush to claim a $7,500 tax credit before it ends. The speaker notes this may lead to a weak Q4, but the market focuses on the immediate quarter.
  • Optimus Robot: A redesign for mass production is underway. The speaker believes Wall Street views Optimus as a "joke," meaning any progress is pure upside for the stock and delays have no negative impact.
  • Tesla Semi: A wider commercial launch is imminent.
  • Energy Storage: This business segment is ramping up successfully.
• The speaker categorizes TSLA as an investment in "buying the best regardless of valuation," similar to how some investors view Palantir (PLTR).
• While acknowledging that many see Tesla as having a "nosebleed valuation," the speaker personally believes the stock is undervalued when looking out to 2030 and beyond.

Takeaways

• The speaker is very bullish on TSLA, arguing that a cluster of powerful catalysts could soon drive the stock higher after a long period of stagnation.
• The investment thesis is twofold: a near-term bet on multiple positive news events in Q3 and a long-term bet on transformative technologies like FSD, Robotaxi, and Optimus that are not yet fully reflected in the stock price.
• Investors should look past traditional valuation metrics and focus on the company's potential to dominate future industries, from AI and robotics to energy.
• The upcoming end of the US tax credit provides a specific, short-term catalyst to watch before the end of Q3.

Bitcoin (BTC)

• Bitcoin is discussed primarily as the underlying asset and core thesis for the MicroStrategy (MSTR) investment.
• The speaker's sentiment is bullish, stating that Bitcoin is "doing just fine" and has stabilized around the $113,000 to $114,000 level (Note: This is likely a misstatement in the transcript, as the price was much lower at the time of recording; the speaker may have meant a future target or was referring to MSTR's Bitcoin cost basis in a confusing way. However, the bullish sentiment is clear).
• The fundamental belief is that Bitcoin has no top because fiat has no bottom. This positions Bitcoin as the ultimate hedge against the long-term devaluation of government-issued currencies.

Takeaways

• The speaker views Bitcoin as a foundational asset for a portfolio designed to protect against inflation and currency debasement.
• The primary way to play this, according to the podcast, is through MicroStrategy (MSTR), which offers a leveraged way to gain exposure to Bitcoin's potential upside.
• The investment is framed as a long-term position, ignoring short-term price volatility in favor of the macro trend of fiat currency losing its value.